Study design: Systematic review and effectiveness analysis. Objectives: Assess the effectiveness of anticonvulsants for the management of post spinal cord injury (SCI) neuropathic pain. Setting: Studies from multiple countries were included. Methods: CINAHL, Cochrane, EMBASE and MEDLINE were searched up to April 2013. Quality assessment was conducted using the Jadad and the Downs and Black tools. Effect sizes and odds ratios were calculated for primary and secondary outcome in the included studies. Results: Gabapentinoids, valproate, lamotrigine, levetiracetam and carbamazepine were examined in the 13 included studies, ten of which are randomized controlled trials. Large effect size (0.873-3.362) for improvement of pain relief was found in 4 of the 6 studies examining the effectiveness of gabapentin. Pregabalin was shown to have a moderate to large effect (0.695-3.805) on improving neuropathic pain post SCI in 3 studies. Valproate and levetiracetam were not effective in improving neuropathic pain post SCI, while lamotrigine was effective in reducing neuropathic pain amongst persons with incomplete lesions and carbamazepine was found effective for relief of moderate to intense pain. Conclusion: Gabapentin and pregabalin are the two anticonvulsants which have been shown to have some benefit in reducing neuropathic pain.
INTRODUCTION
Chronic pain following spinal cord injury (SCI) is common, debilitating and difficult to treat. The estimated number of people with pain following SCI ranges as high as 63-91%. 1 Those with pain are significantly impaired by it and they report a significant impact on health perception, function and quality of life. Spinal cord injured patients affected by pain indicate that pain interferes with their daily activities more severely than the injury itself, 2 and they have a more negative perception of their health than those without pain. 3 Despite the prevalence of pain after SCI and its impact on function and quality of life, patients with SCI indicate that significant pain reduction and relief is difficult to achieve. 2, 4, 5 In a survey of 117 people with traumatic SCI, Jensen et al. 4 report that first-line treatments (e.g., gabapentin) for chronic pain in SCI are associated with minimal pain relief. Similarly, in a postal survey of 575 persons with SCI, Heutink et al. 5 document that high levels of pain persist despite treatment.
Pain following SCI can be neuropathic or nociceptive in origin, and neuropathic pain that occurs below the level of injury is particularly difficult to manage. 4 Anticonvulsants are commonly used for management of neuropathic pain in SCI. 4, 5 Gabapentin and pregabalin, both anticonvulsants, are considered first-line treatment under French guidelines 6 and a proposed algorithm for management of pain after SCI. 7 Lamotrigine and other anticonvulsants are considered second/third line in the management of at or below level neuropathic pain after spinal cord injury. 6, 7 Anticonvulsants have pharmacologic effects on various putative pathophysiologic mechanisms underlying the development of neuropathic pain. 8, 9 Mechanisms of action include sodium and calcium channel modulation, GABA inhibition and suppression of neuronal hyperexcitability. 9 For example, gabapentin inhibits presynaptic calcium channel activation at primary nociceptive afferents in the dorsal horn necessary for central sensitization. 8 Gabapentin also has a partial effect at the sodium channel; 9 sodium channel blockade eliminates ectopic impulses from damaged afferent nociceptors that could lead to the development of neuropathic pain. 8 Although a part of the Canadian Pain Society fourth line recommendations, general neuropathic pain guideline recommendations, previous reviews have noted a lack of evidence for the use of anticonvulsants in the management of below and at-level neuropathic pain after SCI. 6, 7 Evidence for the use of gabapentin and pregabalin is limited and based on small studies. 10, 11 Given the limited evidence on anticonvulsant use for neuropathic pain after SCI 6, 7, 10 and patient surveys that document a lack of perceived effectiveness of these medications, 4 the purpose of this study was to perform a systematic review and if possible a metaanalysis of the effectiveness of anticonvulsants for the management of post-SCI neuropathic pain. Clarity regarding the effectiveness and potential risks of anticonvulsants for neuropathic pain after SCI is particularly important as neuropathic pain has a profound effect on the well-being of many individuals with SCI. 
MATERIALS AND METHODS

Inclusion/exclusion criteria
Published studies were selected for analysis if the following criteria were met: (1) examined the role of anticonvulsants; (2) focused on neuropathic pain; (3) contained persons with SCI; (4) described an intervention; (5) participants were 18 years or older; (6) was written in English language; (7) designed as randomized controlled trials (RCT) or observational design; and (8) measured pain as an outcome. Studies were excluded if: (1) it was a review; or (2) there were less than 3 participants with SCI.
Selection of relevant studies
Following removal of duplicates, two authors (SM and SG) independently reviewed the titles and abstracts retrieved from the electronic search. Where conflict over an inclusion decision arose, a third reviewer (EL) resolved it. Full papers were obtained for records deemed eligible. Figure 1 represents the retrieval and selection of studies.
Study appraisal and data synthesis
Extraction of data was undertaken by two independent reviewers (SM and SG). A data extraction form was created based on previous systematic reviews of pharmacological treatment of chronic pain in general populations containing information on: sample characteristics, study identification, intervention, drug used, statistical analysis, outcome measures and results. A quality assessment was conducted for all RCTs by two independent reviewers using the Jadad quality assessment measure. 12 This tool, which has been validated in a population with pain, consists of three items with a five point quality scale; higher scores represent a higher methodological quality. 12 The Downs & Black 13 scale was used by two independent reviewers to assess quality of nonRCTs. This tool contains 27 items yielding a maximum score of 44. Higher scores reflect a greater level of methodological quality.
Data analysis
Effect sizes for each intervention were provided where possible. The effect size was calculated as a standardized mean difference for each study by subtracting of the control group from the treatment group and dividing by the pooled standard deviation, representing size and direction of the treatment in each study. Data was analyzed using Comprehensive MetaAnalysis Software, V2. As outcomes were heterogeneous, we could not conduct a pooled effects analysis. Studies included in effectiveness analysis (n = 9) Figure 1 Retrieval and selection of records for inclusion.
Anticonvulsants for pain management S Guy et al Gabapentin, amitriptyline, diphenhydramine. 6 groups with differing order of drug treatment. Each drug was administered for 9 wks with 1 washout week before and after each drug treatment, for a total of 31 wks. The maximum doses were 50mg, 3 Â per day for amitriptyline; 1200mg, 3 Â per day for gabapentin; 25mg, 3 Â per day diphenhydramine (control). VAS; NRS; CESD-SF At week 8, amitriptyline was more effective than diphenhydramine (P ¼ 0.35) in patients with high baseline CESD-SF scores. Amitriptyline was not significantly more effective than gabapentin (P ¼ 0.61). Gabapentin no more effective than diphenhydramine (P ¼ 0.97).
Anticonvulsants for pain management S Guy et al
As a result, an effectiveness analysis was run. The criteria used to interpret the resulting effect sizes were those outlined in Cohen (1988) . 14 
RESULTS
Study design and quality
A comparison of a treatment and control group was undertaken in 10 studies. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The most popular design for intervention studies which met inclusion criteria was the double-blind crossover trial (n ¼ 4), 16, 18, 19, 23 followed by the double-blind parallel-group trial (n ¼ 3). 21, 22, 24 One study had a double-blind, triple crossover RCT design. 20 Other designs included: 1 pre-post study, 25 1 longitudinal observational study 26 and 1 retrospective chart review. 27 See Table 1 for a summary of included studies and methodological quality of each article. Power calculations were provided in 7 studies. 15, [18] [19] [20] [21] [22] 24 Sample size ranged from 14 23 to 219 15 participants.
Gabapentinoids were examined in 9 15, 19, 20, [22] [23] [24] [25] [26] [27] of the 13 studies. The following drugs were examined in the remaining studies: valproate, 16 lamotrigine, 17 levetiracetam, 18 and carbamazepine. 21 All studies used an oral route of administration.
Participant characteristics
Baseline characteristics were generally well described in all included studies. For instance, age was provided in all but one study, 26 age ranged from a mean of 32.5 years 16 -54.7 years. 24 Sex categorization of the sample was reported in all 13 studies-ratio of male to female participants can be seen in Table 1 with a few studies including almost double the number of males compared to females. Information on 
The proportions of patient with a 4-30% reduction and a 4-50% reduction in pain score from baseline at endpoint were significantly higher in treatment group than control group. At endpoint, 15.9% patients in treatment group had severe pain compared with 43.3% in control. Over 1/3 patients in treatment group had no/mild pain at endpoint compared with 10.5% in control group. Tai et al. 23 USA Double-blind, crossover RCT Jadad: 5/5 14/14 SCI 6:7 Neuropathic Gabapentin Treatment: 4-week course (3 Â daily; progressively increased from 300-600 mg per day) followed by 2week washout period, and crossover of 4 wks medication/placebo. Control: 4 week course of placebo (3 Â daily) followed by 2-week washout period and crossover of 4 wks medication/placebo. NPS Significant reduction in 'unpleasant feeling' with gabapentin compared to placebo (P ¼ 0.028). Trends of reductions with gabapentin vs placebo for 'pain intensity' (P ¼ 0.094) and 'burning feeling' (P ¼ 0.065). No other differences for any other pain descriptors.
To et al. completeness of injury was provided in 7 studies. 15, 17, 18, 21, [24] [25] [26] Number of participants with complete injury ranged from 5 26 -106, 15 while number of participants with incomplete injury ranged from 10 17,24 -105. 15 Level of injury (tetraplegia or paraplegia) was reported in 7 of the 13 studies; 16, 20, 22, 23, [25] [26] [27] with a range of 4 16 -58 22 participants with tetraplegia and 6 23 -79 22 for participants with paraplegia. Time since injury was recorded in 5 of the 13 studies, 17, 19, 20, 22, 23 with a duration range of 1 month-396 months post injury. The cause of spinal cord injury was reported in 4 of the 13 studies; 15, 18, 21, 23, 25 these included: hemorrhage, surgery, infection, tumor, firearm and other weapons, falls, prolapsed disk, sports, diving, transverse myelitis, ischemia and motor vehicle accidents. When reporting the type of pain being examined, Cardenas et al. 15 was the only article to mention taxonomy, that is, the Bryce-Ragnarsson taxonomy. Onset of pain post injury was mentioned in 10 of the 13 studies [15] [16] [17] [18] 20, 22, 23, 25, 27 with a duration range (when months/years are attributed to pain description) ofo6 months-45 months.
Effectiveness on primary outcome
Effect size calculations were possible for 10 studies (Table 2) , while the results of the remaining studies were descriptively provided in Table 1 . Overall, 9 studies evaluated the effects of gabapentin and pregabalin on improving pain outcomes after SCI. Of these, 6 studies examined the effectiveness of gabapentin for pain after SCI. 19, 20, 23, [25] [26] [27] Four of these studies found large effect size (0.873-3.362) for improvement in pain relief 19, 23, 25, 27 with effects maintained for up to 24 weeks. Data to calculate an effect size was not available for Putzke et al. 26 ; however, the study reported improvement in pain by 2 points or more after gabapentin treatment in 14 of 21 participants. Ahn et al. 25 found gabapentin was effective in improving pain among those individuals with chronic pain (46 months) and those with more subacute pain (o6 months) for up to 8 weeks. The only study using an active placebo (Benadryl) as the control intervention found no significant improvement in pain post gabapentin treatment. 20 Pregabalin was shown to have moderate to large effect (0.695-3.805) on improving neuropathic pain after SCI in 3 studies. 15, 22, 24 The remaining 4 studies examined less commonly utilized anticonvulsants in pain management after SCI. [16] [17] [18] 21 Drewes et al. 16 found valproate was not effective in improving neuropathic pain after SCI when compared to control. Finnerup et al. 17 reported lamotrigine was only effective in reducing neuropathic pain among individuals with incomplete lesions when compared to those with complete lesions (d ¼ 1.374±0.258-2.489, Po0.016) at 20 weeks post treatment. No significant improvement in pain was seen in participants with at and below level neuropathic pain with the administration of levetiracetam. 18 Carbamazepine significantly improved pain among individuals with moderate to intense neuropathic pain at one month post treatment compared to the control group. 21 However, these improvements were not sustained over a 3 and 6 month period.
Secondary outcomes
Sleep interference was shown to improve with the use of both gabapentin 25 and pregabalin; 22 the use of lamotrigine showed no significant improvement in sleep interference. 17 Two studies examined the effect of pregabalin on the Hospital Anxiety and Depression Scale (HADS) anxiety subscale and depression subscale. 15, 22 Cardenas et al. 15 found treatment with pregabalin had a large effect size in improving both anxiety and depression at week 16; however, Siddall et al. 22 found no effect at 12 weeks. Vranken et al. 24 found significant improvement in EuroQOL (EQ-5D utility) post pregabalin treatment at week 4 but no significant improvement in the Pain Disability Index. For more details on secondary outcomes see Table 3 .
Adverse events
Effect size data was available in 4 studies examining the adverse events of anticonvulsants. 15, 17, 19, 24 No significant difference in adverse event occurrence was noted between the control group and lamotrigine 17 or gabapentin. 19 However, Cardenas et al. 15 receiving pregabalin were significantly more likely to experience dizziness (3.7 times), fatigue (8.2 times), peripheral edema (4.6 times) and somnolence (3.3 times) than those in the control group (see Table 4 ).
found individuals
DISCUSSION
Thirteen studies examining the efficacy of anticonvulsants for pain relief post SCI were identified. The most commonly studied anticonvulsants are gabapentin and pregabalin which are recommended in clinical practice guidelines as first-line treatments. Research evidence is more limited on the remaining anticonvulsants: valproate, lamotrigine, levetiracetam and carbamazepine. Varying levels of effectiveness for gabapentinoids can be seen; 4 studies show large effect sizes (0.873-3.362) for pain improvement with gabapentin treatment alone and moderate to large effect sizes for pregabalin (0.695-3.805). The effectiveness of valproate, lamotrigine, levetiracetam and carbamazepine is less certain, given we had to rely on only one trial that met inclusion criteria for each. That being said, based on single studies, valproate and levetiracetam were not successful in improving pain, 16, 18 lamotrigine was effective at reducing neuropathic pain among individuals with incomplete lesions, 17 and carbamazepine was found to be effective in individuals with moderate to intense neuropathic pain. 21 In studies which examined subgroups, lamotrigine and pregabalin were more effective in persons with incomplete injury. 17, 22 For those authors reporting adverse events, no significant difference was found in lamotrigine or gabapentin when compared to controls. In one study, pregabalin was associated with blurred vision, drowsiness, fatigue, peripheral edema and dizziness. 15 Rintala et al. 20 was the only study to find gabapentin was no more effective in relieving pain intensity than the placebo diphenhydramine at week 8 of the trial, and to use an active control. The authors state diphenhydramine was used as it has similar side effects to that of amitryptiline and gabapentin; however, it is not a pain reliever. This active placebo has a half-life of 3-12 h in comparison to gabapentin's 6-8 h and amitryptiline's 24-70 h. This placebo was placed in capsules identical to the other 2 study medications. Two early crossovers were thought to be the result of possible side effects (palpitations, fatigue, dizziness and drowsiness) caused by the placebo. Bjorkedal and Flaten 28 explored the concept of an active placebo (i.e., mimicking side effects of an active treatment) in reducing pain and found an increase in reduction in pain intensity. This within-subjects balanced placebo design tested the hypothesis that expectations and responses to a placebo (in this case, caffeine) can be enhanced by drug side effects. Results showed using an active placebo versus an inert placebo can produce differing treatment effects. Future studies are best conducted using an active placebo to establish effectiveness of these medications.
Gabapentinoids were found to have a positive effect on sleep interference. 22, 25 Two factors accounting for this appear to be a reduction of pain levels and drug side effects. Both pregabalin and gabapentin can lead to fatigue, sleepiness, sedation and somnolence. 15, 18, 19, 24 Cardenas et al. 15 and Levendoglu et al. 19 found the treatment group was 3.3 and 8 times, respectively, more likely to experience sedation than the placebo control group.
Current trials
Three relevant trials were retrieved through our grey literature database search. Green 29 is conducting a clinical trial in Spain examining the efficacy of pregabalin for the treatment and prevention of neuropathic pain as a result of SCI. This proposed study is a randomized, double-blind, crossover trial comparing pregabalin treatment with a placebo. The primary outcome measure is daily at-level pain intensity as measured by a numerical rating scale (0-10). A Canadian double-blind, randomized, placebo-controlled trial is testing the efficacy of pregabablin in the prevention of neuropathic pain post SCI across a rehabilitation center setting. 30 A study headed by Pfizer Japan is assessing pregabalin for the treatment of central neuropathic pain in a non-randomized, single group, openlabel trial. 31 
Strengths and limitations
This systematic review attempts to collate all available data regarding the effectiveness of anticonvulsant medications for the relief of pain post spinal cord injury. Notably, we have not restricted interventional studies to RCTs but have also included other study designs. Quality of methodological design of interventional studies has been assessed using validated tools. Outcome measures proved to be too heterogeneous to be compared and as a result the data could not be pooled. However, effect sizes and odds ratio were calculated.
Recommendations for future research It appears well established that gabapentin and pregabalin are the two anticonvulsants which have been shown to have some limited benefit. The role of combination treatment may improve the analgesic effect of these medications. Studies comparing different anticonvulsants, particularly for some subgroups, may be helpful. The utility of less commonly prescribed anticonvulsants has not yet adequately been established.
Given evidence showing a difference in treatment effect may exist when using an active placebo design versus an inert placebo design, it would be beneficial to incorporate an active placebo when testing the effect of anticonvulsants in relieving pain post spinal cord injury. Amongst the 10 RCTs reviewed, only one study utilized an active placebo design.
Amongst all the anticonvulsants included in this review, the strongest evidence for the management of pain post SCI points to gabapentioids. Varying levels of the effectiveness of gabapentinoids can be seen, with 4 trials showing large effect sizes. Being cognizant of the very limited work done with other anticonvulsants, carbamazepine and lamotrigine were found to be effective in relieving pain post SCI. The lesser-studied anticonvulsants merit further investigation.
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